Joel Greenblatt’s Quince Therapeutics QNCX Stock Holding History

Joel Greenblatt’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-18	Closed	-$335K	–	1220
2021 Q3	$335K	Buy	+18	New	+$286K	0.01%	781

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Joel Greenblatt's QNCX Position: Q4 2021 in Review

Joel Greenblatt sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 18 shares — an estimated $335K sold.

Joel Greenblatt first reported a position in QNCX in Q3 2021 and held it in 1 quarter. The position peaked at $335K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

Joel Greenblatt reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
Joel Greenblatt sold 18 Quince Therapeutics shares in Q4 2021, an estimated $335K.
Joel Greenblatt first reported a position in Quince Therapeutics in Q3 2021 and held it in 1 quarter.
Joel Greenblatt's Quince Therapeutics position peaked at $335K in Q3 2021.
97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Gotham Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.